Compounds > eremomycin aglycone
Page last updated: 2024-12-08

eremomycin aglycone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID147915
CHEMBL ID264202
MeSH IDM0161476

Synonyms (7)

Synonym
(2-amino-2-oxo-ethyl)-chloro-hexahydroxy-[[(2r)-4-methyl-2-(methylamino)pentanoyl]amino]-pentaoxo-[?]carboxylic acid
eremomycin aglycone
vancomycin, 44-o-de[2-o-(3-amino-2,3,6-trideoxy-3-c-methyl-.alpha.-lyxo-hexopyranosyl)-.beta.-glucopyranosyl]-19-dechloro-
CHEMBL264202
vancomycin, 44-o-de(2-o-(3-amino-2,3,6-trideoxy-3-c-methyl-alpha-l-lyxo-hexopyranosyl)-beta-d-glucopyranosyl)-19-dechloro-
119789-44-5
DTXSID90152587
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID247523Cytostatic activity to the compound against CEM cell line2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID244766Minimal cytotoxic concentration to cause an alteration in C3H/3T3 cell line morphology2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID246121Effective concentration against human immunodeficiency virus type 22005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID764931Binding affinity to N,N'-Ac2-L-Lys-D-Ala-Gly model of cell wall ligand by UV-difference assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Investigation into the functional impact of the vancomycin C-ring aryl chloride.
AID245098Minimum inhibitory concentration against glycopeptide resistant enterococci 560 Enterococcus faecalis2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID764933Binding affinity to N,N'-Ac2-L-Lys-D-Ala-D-Ala model of cell wall ligand by UV-difference assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Investigation into the functional impact of the vancomycin C-ring aryl chloride.
AID246125Effective concentration against human immunodeficiency virus type 1 2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID209587Antibacterial activity against Streptococcus haemolyticus 602 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID68068Antibacterial activity against glycopeptide resistant Enterococcus faecium 569 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID68069Antibacterial activity against glycopeptide susceptible Enterococcus faecium 568 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID764932Binding affinity to N,N'-Ac2-L-Lys-D-Ala-D-Phe model of cell wall ligand by UV-difference assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Investigation into the functional impact of the vancomycin C-ring aryl chloride.
AID764935Antimicrobial activity against vancomycin-sensitive Staphylococcus aureus ATCC 25923 after 24 hrs2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Investigation into the functional impact of the vancomycin C-ring aryl chloride.
AID207011Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3798 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID206213Antibacterial activity against Staphylococcus epidermis 533 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID244824Minimum inhibitory concentration against 602 Staphylococcus haemolyticus2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID245127Minimum inhibitory concentration against 559 glycopeptide susceptible enterococci Enterococcus faecalis2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID246043Effective concentration against Moloney sarcoma virus2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID247534Cytostatic activity against L1210 cell line2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID66902Antibacterial activity against glycopeptide resistant Enterococcus faecalis 560 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID245083Minimum inhibitory concentration against glycopeptide resistant enterococci 569 Enterococcus faecium2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID66903Antibacterial activity against glycopeptide susceptible Enterococcus faecalis 559 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
AID245108Minimum inhibitory concentration against glycopeptide susceptible enterococci 568 Enterococcus faecium2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID244818Minimum inhibitory concentration against 533 Staphylococcus epidermidis2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID245133Minimum inhibitory concentration against glycopeptide intermediate-resistant 3798 Staphylococcus aureus2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID245132Minimum inhibitory concentration against glycopeptide intermediate-resistant 3797 Staphylococcus aureus2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID764934Binding affinity to N,N'-Ac2-L-Lys-D-Ala-D-Ser model of cell wall ligand by UV-difference assay2013Bioorganic & medicinal chemistry letters, Sep-01, Volume: 23, Issue:17
Investigation into the functional impact of the vancomycin C-ring aryl chloride.
AID247548Cytostatic activity to the compound against Molt4/C8 cell line2005Journal of medicinal chemistry, Jun-02, Volume: 48, Issue:11
Structure-activity relationship studies of a series of antiviral and antibacterial aglycon derivatives of the glycopeptide antibiotics vancomycin, eremomycin, and dechloroeremomycin.
AID207010Antibacterial activity against glycopeptide intermediate resistant Staphylococcus aureus 3797 strain2003Journal of medicinal chemistry, Mar-27, Volume: 46, Issue:7
Role of the glycopeptide framework in the antibacterial activity of hydrophobic derivatives of glycopeptide antibiotics.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (33.33)18.7374
1990's1 (16.67)18.2507
2000's2 (33.33)29.6817
2010's1 (16.67)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.52

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.52 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.52)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
vancomycin
Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.		2.4420glycopeptideantibacterial drug;
antimicrobial agent;
bacterial metabolite
a 82846a
[no description available]		2.940
aglucovancomycin b
aglucovancomycin B: degradation product of vancomycin B; structure in first source. vancomycin aglycone : A peptide antibiotic that is vancomycin lacking the disaccharide moiety.		2.0810cyclic ether;
heterodetic cyclic peptide;
peptide antibiotic;
peptide zwitterion;
polyphenol		metabolite
glycosides
[no description available]		1.9710
teicoplanin aglycone
[no description available]		2.0110oligopeptide
ConditionIndicatedRelationship StrengthStudiesTrials
Infections, Staphylococcal
[description not available]		02.0810
Staphylococcal Infections
Infections with bacteria of the genus STAPHYLOCOCCUS.		02.0810